TENX Tenax Therapeutics, Inc.

0.48
0  0%
Previous Close 0.48
Open 0.47
Price To book 0.79
Market Cap 13.43M
Shares 28,120,000
Volume 171,342
Short Ratio 2.07
Av. Daily Volume 1,613,560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax CEO resigns, company to review 'strategic alternatives'
  2. Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update
  3. TENX: 2016 Results; Subgroup Analysis Shows CABG Survival Benefit
  4. Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update
  5. Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017
  6. Tenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update
  7. TENX: Tenax Reports LEVO-CTS Topline Results
  8. Under Armour, Rite Aid Fall into Tuesday’s 52-Week Low Club
  9. Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
  10. Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology
  11. Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
  12. Tenax Therapeutics, Inc. Review of Clinical Trials and Financials
  13. Is KemPharm Inc (KMPH) A Good Stock To Buy?
  14. TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
  15. Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery
  16. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  17. Investor Calendar Invites You to the Tenax Therapeutics Third Quarter 2016 Business Review and Update on Thursday, November 10, 2016
  18. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update
  19. TENX: LeoPARDS Trial Fails Endpoints; Year End 2016 Readout for LEVO-CTS.